News

Article

Clinical Quiz: 2022 ACR Vaccine Recommendations for People With Rheumatic and Musculoskeletal Disease

Key Takeaways

  • Over 58.5 million Americans have rheumatic diseases, with 300,000 children affected by juvenile arthritis.
  • Vaccination is a critical consideration in treating RMDs, especially for patients on immunosuppressants.
SHOW MORE

This clinical quiz, our first in a series of 3, focuses on recommendations for specific vaccines from the 2022 ACR vaccination guidelines.

HCPLive clinical quiz image. Credit: HCPLive

Over 58.5 million people in the United States have been diagnosed with rheumatic diseases (RMDs), including an estimated 300,000 children living with some type of juvenile arthritis.1

There are many factors to consider when treating patients with RMDs and musculoskeletal diseases, especially people that may be taking immunosuppressants. One such factor is vaccinations.

In 2022, the American College of Rheumatology (ACR) issued new guidance and recommendations for vaccinations in people with RMDs and musculoskeletal diseases. The 16-page document, which was the group's first new guideline on the topic since 2022, contained 19 recommendations, including 3 strong recommendations. In this clinical quiz, the first in a series of 4 based on the guideline, we test your knowledge on recommendations for influenza, pnuemococcal, recombinant varicella-zoster virus, and human papillomavirus vaccinations.2

What is the recommendation for influenza vaccination in patients with RMD aged ≥65 years?

A) Regular-dose influenza vaccination

B) High-dose or adjuvanted influenza vaccination

C) No vaccination

D) Only if the patient is symptomatic



References

1. ACR. American College of Rheumatology Releases 2022 Rheumatic Disease Report Card. News release. September 15, 2022. https://rheumatology.org/press-releases/american-college-of-rheumatology-releases-2022-rheumatic-disease-report-card

2. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arth Care Res. 2023(75)3. 449–464. doi: 10.1002/acr.25045

Related Videos
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
Davide Matino, MD, MSc: Bringing Marstacimab Treatment to Hemophilia A and B
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Marlyn Mayo, MD: Improving Pruritus Management in PBC Care
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.